A Phase 2 interventional study of Afimkibart in Crohns Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 11 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Crohn Disease by Hoffmann-La Roche — 3 open to participants now, 4 under way, 3 of them phase 3. Crohn Disease · Hoffmann-La Roche.
Among the 10 studies in Crohn Disease by Hoffmann-La Roche, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 3 in phase 2, and was the 7th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →3 of the 10 studies in Crohn Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 5 more countries
Ages 2–17
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 24 more countries
Ages 16–80
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 35 more countries
Ages 16–80
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 122 across the 10 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
1 of the studies in Crohn Disease by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05910528Hoffmann-La RocheAfimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Crohn Disease by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Afimkibart
Drug: Afimkibart
Afimkibart will be administered during the Induction, Maintenance and OLE period.
Also known as: RO7790121, RVT-3101, PF-06480605
Incidence of Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE) and AE Leading to Discontinuation
Time frame: Until end of study, approximately 5 years
Proportion of Participants Achieving Endoscopic Response
Endoscopic response defined as decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) \>=50% from Baseline at Week 14
Time frame: Week 14
Proportion of Participants Achieving Clinical Remission by Crohn's Disease Activity Index (CDAI)
Clinical remission defined as CDAI \<150 at Week 14
Time frame: Week 14
Proportion of Participants Achieving Clinical Remission by Patient Reported Outcome 2 (PRO2)
Clinical remission by PRO2 defined as average daily very soft or liquid stool frequency (SF) \<= 2.8 and abdominal pain (AP) score \<=1, and not worse than Baseline at Week 14.
Time frame: Week 14
Trough Concentration (Ctrough)
Time frame: Up to Week 64
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 41 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimkibart